In 2018 , Mapp Biopharmaceutical, Inc. (MappBio), was awarded a contract (HHSO100201800024C) of $14.8 million with options for an additional $32.0 million by the Biomedical Advanced Research and Development Authority (BARDA) re the Sudan Ebolavirus ..
MBP134 is a combination of two human monoclonal antibodies (mAbs) being developed with an initial indication of treatment of disease caused by Sudan virus . The mAbs were identified from a survivor of the 2013-2016 Ebola Virus Disease outbreak"
🤔
via a collab between a team at Adimab LLC (Lebanon, NH) led by Dr. Laura Walker, a MappBio team led by Dr. Zachary Bornholdt, & a group of academic & gov't partners that included NIAID supported Centers of Excellence for Translational Research." 🤔 mappbio.com/mappbio-announ…
Google AI : " Pardis Sabeti is a computational geneticist and evolutionary biologist..Her work during the 2014 Ebola outbreak in West Africa was particularly notable, where her team generated the first large-scale genomic dataset of the virus"🎶
"In 2011, a court approved a creditors arrangement confirming developer Moshe Aharoni as the purchaser of the rights of Migdal Hazohar, a company owned by David Appel that had been under a stay of proceedings..
Aharoni paid NIS 330 million for the rights, NIS 235 million of which was for land in Givat Shmuel on which Aharoni is currently building a residential housing project in cooperation with Africa-Israel Investments Ltd. (TASE:AFIL)."..
The company became the subject of newspaper coverage in 2008 , for its association with the construction of Israeli settlements on the West Bank."..
"Prime Minister Benjamin Netanyahu says during testimony in his corruption trial that he encouraged US businessman Sheldon Adelson to invest in the Israeli media market in order to “diversify” the news coverage."🎶 timesofisrael.com/liveblog_entry…